Agios Pharmaceuticals (AGIO) Return on Sales (2012 - 2026)

Agios Pharmaceuticals' Return on Sales history runs 15 years deep, the most recent figure standing at 0.07% for Q1 2026.

• Quarterly Return on Sales rose 6.0% year-over-year to 0.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.07% (down 24.0% YoY) and the FY2025 annual result came in at 0.08%, down 26.0% from the prior year.
• Return on Sales was 0.07% for Q1 2026 at Agios Pharmaceuticals, down from 0.05% in the prior quarter.
• Across five years, Return on Sales topped out at 1.06% in Q3 2024 and bottomed at 0.16% in Q1 2023.
• A 5-year average of 0.02% and a median of 0.1% in 2025 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales soared 118 bps — and 2025, when it plunged 114 bps.
• Agios Pharmaceuticals' Return on Sales stood at 0.0% in 2022, then sank by 3490 bps to 0.14% in 2023, then soared by 33 bps to 0.09% in 2024, then jumped by 40 bps to 0.05% in 2025, then slumped by 32 bps to 0.07% in 2026.
• Business Quant data shows AGIO's Return on Sales at 0.07% in Q1 2026, 0.05% in Q4 2025, and 0.08% in Q3 2025.